Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

#4625

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Aim(s): To study the efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with GEP-NET, TC, and AC.

Materials and methods: A systematic review was conducted to gather efficacy and safety data for CAPTEM use in GEP-NET and pulmonary NEN from 2005-2024. Retrospective data from the NETwerk (Belgian ENETS CoE) database, comprising 36 patients with GEP-NET grades 1-3 and pulmonary NEN treated with CAPTEM between June 2016 and January 2024, was also analysed.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,